Systemic light chain amyloidosis myopathy responsive to daratumumab monotherapy

BACKGROUND AND PURPOSE: Amyloid myopathy is a rare and severe manifestation of systemic light chain (AL) amyloidosis. Early diagnosis and staging are mandatory for optimal therapy, given the rapid progression of muscle weakness. Despite the efficacy of bortezomib‐based treatment regimens, there is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Chitimus, Diana Maria, Berling, Edouard, Garderet, Laurent, Venturelli, Nadia, Malfatti, Edoardo, Authier, François Jérôme, Nicolas, Guillaume, Laforêt, Pascal, Lefeuvre, Claire
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Muscle and NMJ disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098764/
https://www.ncbi.nlm.nih.gov/pubmed/36403110
http://dx.doi.org/10.1111/ene.15640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098764/
https://www.ncbi.nlm.nih.gov/pubmed/36403110
http://dx.doi.org/10.1111/ene.15640

Ejemplares similares